UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
___________________________
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
March
11, 2005
Date of
Report (Date of earliest event reported)
Discovery
Laboratories, Inc.
(Exact
name of Registrant as specified in its charter)
|
Delaware |
000-26422 |
94-3171943 |
|
(State
or other jurisdiction
of
incorporation) |
(Commission
File Number) |
(IRS
Employer
Identification
Number) |
2600
Kelly Road, Suite 100
Warrington,
Pennsylvania 18976
(Address
of principal executive offices)
(215)
488-9300
(Registrant's
telephone number, including area code)
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
5.02. |
Departure
of Directors or Principal Officers; Election of Directors; Appointment of
Principal Officers. |
On March
11, 2005, the Board of Directors of Discovery Laboratories, Inc. (the “Company”)
appointed Kathleen A. McGowan, 44, as the Company’s Controller and principal
accounting officer. Ms. McGowan replaced Cynthia Davis, who remains with the
Company in a different capacity. Ms. McGowan is an at-will employee of the
Company and she will be paid an annual base salary of $140,000.
Prior to
her appointment as Controller and principal accounting officer, Ms. McGowan
served as Director of Financial Planning and Analysis of the Company since June
7, 2004. Previously, she was Director of Financial Analysis at Claneil
Enterprises, Inc., a private equity investment firm, where she evaluated
investment opportunities and provided financial analysis, valuation and
management of the investment portfolio. From 1996-2000, Ms. McGowan was the
Financial Controller at The Liposome Company, Inc., a publicly held biotech
company acquired by Elan Corporation, plc, where she managed the internal and
external financial reporting and analysis, internal controls and accounting
functions, and provided financial oversight to the sales & marketing
organization. Ms. McGowan received her B.S. in Finance and Accounting from
Drexel University and an MBA in Finance from Fairleigh Dickinson
University.
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| Discovery Laboratories, Inc. | ||
| |
|
|
| By: | /s/ Robert J. Capetola | |
|
Name: Robert J. Capetola, Ph.D. | ||
| Title: President and Chief Executive Officer | ||
Date:
March 17, 2005
3